News from novartis A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Aug 05, 2020, 17:02 ET Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis

Novartis today announced that The New England Journal of Medicine (NEJM) published the positive results from the ASCLEPIOS I and II studies...


May 29, 2020, 08:01 ET Novartis announces long-term, relapse-free survival benefit for high-risk, stage III melanoma patients treated with Tafinlar® + Mekinist® following surgery

Novartis announced today updated results from the landmark COMBI-AD clinical trial, demonstrating that treatment with Tafinlar® (dabrafenib) and...


May 27, 2020, 07:30 ET Novartis announces new late-breaking ofatumumab data at EAN underscoring commitment to advancing treatment of relapsing forms of multiple sclerosis (RMS)

Novartis announced today that new ofatumumab data from the Phase III ASCLEPIOS trials and the Phase II APLIOS trial were presented virtually at the...


May 27, 2020, 07:00 ET Novartis Kisqali® shows overall survival benefit in HR+/HER2- advanced breast cancer with consistent findings in patients with more aggressive disease

Novartis today announced a new exploratory subgroup analysis of the Phase III MONALEESA-3 and MONALEESA-7 trials, to be presented during the ASCO20...


May 14, 2020, 09:12 ET Novartis data at ASCO and EHA showcase bold approaches to reimagine cancer and blood disorders through multiple therapeutic platforms

Data from more than 110 abstracts, including Novartis-sponsored and investigator-initiated trials, will be presented during the upcoming American...


May 06, 2020, 14:38 ET Novartis announces FDA approval of MET inhibitor Tabrecta™ for metastatic non-small cell lung cancer with METex14

Novartis announced today that the US Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib, formerly INC280), an oral MET inhibitor for...


May 05, 2020, 06:00 ET Novartis apresenta proposta de inclusão de medicamento biológico para o tratamento da enxaqueca no rol da saúde suplementar

Muito mais que uma dor de cabeça, a enxaqueca é uma doença crônica neurológica que pode ser incapacitante durante os períodos de crise....


Mar 03, 2020, 07:52 ET Acesso a tratamento para câncer raro no sangue poderá ser ampliado no SUS, hoje cuidado é apenas paliativo

A Comissão Nacional de Incorporação de Tecnologias (CONITEC) abriu consulta pública para avaliar a incorporação da terapia-alvo ruxolitinibe para o...


Jan 16, 2020, 03:00 ET Public-Private Collaboration Commits to Accelerate Access to Health Services in Africa, Reaching 1.7 Million People

Johnson & Johnson, Lilly, Novartis, Pfizer, GSK and the Bill & Melinda Gates Foundation have joined forces with Last Mile Health and Living Goods to...


Jan 02, 2020, 11:35 ET Governo avalia incorporação de medicamentos já disponíveis na rede privada para tratamento de câncer de pele agressivo no SUS

Durante o Dezembro Laranja, mês que marca a Campanha Nacional de Prevenção ao Câncer da Pele, a Comissão Nacional de Incorporação de Tecnologias...


Nov 13, 2019, 08:00 ET Novartis launches PsO at Work with music icon Cyndi Lauper to bring to life the impact psoriasis can have in the workplace

Novartis announced today it has partnered with Grammy, Tony and Emmy award-winning singer, songwriter, actress and activist Cyndi Lauper to launch...


Oct 08, 2019, 09:00 ET Novartis STEP Program™ now accepting submissions for proposals that address unmet patient needs in cancer biomarker testing

Novartis is inviting patient advocacy organizations to submit proposals for programs that offer to expand and improve understanding of biomarker...


Sep 29, 2019, 10:35 ET Novartis Kisqali® delivers consistently superior overall survival - MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients

Novartis today announced results from the MONALEESA-3 trial, which showed Kisqali® (ribociclib) achieved statistically significant improvement in...


Sep 19, 2019, 03:00 ET AveXis presents new data at EPNS continuing to show significant therapeutic benefit of Zolgensma® in prolonging event-free survival now up to 5 years of age in patients with spinal muscular atrophy (SMA) Type 1

New interim data from SPR1NT study supports critical importance of early intervention in pre-symptomatic SMA patients, leading to age‑appropriate...


Jul 25, 2019, 10:46 ET Falta de acesso ao exame de monitoramento para leucemia será avaliada pelo Governo

A Comissão Nacional de Incorporação de Tecnologias no SUS (Conitec) acaba de abrir uma consulta pública para avaliar a incorporação de exame que...


Jul 11, 2019, 13:00 ET Novartis Offers Free Genetic Mutation Testing Program for Advanced Melanoma Patients; Results Can Help Doctors and Patients Making Cancer Treatment Decisions

The Know Now Testing Program, a Novartis initiative in collaboration with Quest Diagnostics, offers genetic mutation testing at no cost for all...


May 24, 2019, 13:21 ET AveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and Families

AveXis, a Novartis company, today announced innovative access programs for Zolgensma® (onasemnogene abeparvovec-xioi) for the treatment of pediatric...


May 16, 2019, 09:11 ET Novartis data at ASCO and EHA demonstrate novel approaches to reimagining medicine in cancer and serious blood disorders

Novartis will present data from across its oncology portfolio at the upcoming 55th Annual Meeting of the American Society of Clinical Oncology...


May 16, 2019, 07:30 ET Five nonprofit organizations to receive up to $250,000 through Novartis STEP Program™ to support sickle cell patient initiatives

Novartis today announced that five nonprofit organizations will receive a total of nearly $250,000 in funding through the company's STEP (Solutions...


May 11, 2019, 17:47 ET Novartis issues voluntary nationwide recall of Promacta® 12.5 mg for oral suspension due to potential peanut contamination

Novartis today announced a voluntary recall of three lots of Promacta (eltrombopag) 12.5 mg for oral suspension to the consumer level. The oral...


Apr 15, 2019, 16:05 ET Novartis announces FDA filing acceptance and Priority Review of brolucizumab (RTH258) for patients with wet AMD

Novartis announced that the U.S. Food and Drug Administration (FDA) accepted the company's Biologics License Application (BLA) for brolucizumab...


Apr 01, 2019, 16:05 ET AveXis expands world-leading gene therapy manufacturing capacity with purchase of advanced biologics therapy manufacturing campus in Longmont, Colorado

AveXis, a Novartis company, today announced it signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont,...


Mar 27, 2019, 00:40 ET Novartis receives FDA approval for Mayzent® (siponimod), the first oral drug to treat secondary progressive MS with active disease

Novartis today announced that the US Food and Drug Administration (FDA) has approved Mayzent® (siponimod) for the treatment of relapsing forms of...


Jan 08, 2019, 03:06 ET Novartis investigational therapy crizanlizumab (SEG101) receives FDA Breakthrough Therapy designation for the prevention of vaso-occlusive crises in sickle cell disease

Novartis announced today that the US Food and Drug Administration (FDA) has granted crizanlizumab (SEG101) Breakthrough Therapy designation for the...


Dec 08, 2018, 08:05 ET Novartis data demonstrates consistent efficacy and tolerability of Kisqali® combination therapy in HR+/HER2- advanced breast cancer in patients with difficult-to-treat visceral disease

Novartis today announced data from subgroup analyses of the three pivotal Phase III MONALEESA trials showing that Kisqali® (ribociclib) plus...